# How Gilead Stabilized the HIV Combination Pill Truvada

> A patent detailing a stable, fixed-dose combination of two HIV drugs, tenofovir disoproxil fumarate and emtricitabine, designed to prevent chemical breakdown in a single tablet.

- **Patent:** US 9744181
- **Original title:** Compositions and methods for combination antiviral therapy
- **Owner:** Gilead Sciences Inc
- **Granted:** 2017
- **Status:** Active
- **Times cited:** 0
- **Field:** pharmaceutical, biotech

## What it does

This patent describes a specific pharmaceutical formulation that combines two potent antiviral drugs, tenofovir disoproxil fumarate (TDF) and emtricitabine, into a single, stable tablet. A major challenge in combining these drugs is that they can chemically react with each other or degrade when exposed to heat and humidity, rendering the medication ineffective. The patent specifies a precise mixture of excipients—inactive substances like pregelatinized starch, croscarmellose sodium, and lactose monohydrate—that act as a protective matrix. By maintaining these specific ratios and using a desiccant during storage, the tablet achieves a high level of chemical stability, ensuring less than 5% degradation even after six months in harsh conditions.

## What it does NOT cover

- Does not cover the individual chemical compounds tenofovir disoproxil fumarate or emtricitabine themselves.
- Does not cover liquid formulations or other non-tablet delivery methods for these drugs.
- Does not cover combinations that do not meet the specific stability threshold of less than 5% degradation under the stated temperature and humidity conditions.
- Does not cover generic combinations that use different excipients or ratios outside of the specific formulations claimed.

## The clever bit

The innovation lies in the precise selection of excipients that prevent the two active ingredients from interacting chemically, effectively 'locking' them in a stable state within the tablet matrix.

## Real-world examples

1. Truvada
2. Atripla (which includes a third agent, efavirenz)

## Why it matters

This technology is the backbone of Truvada, a landmark medication for both HIV treatment and pre-exposure prophylaxis (PrEP). By combining two drugs into one pill, it significantly improved patient adherence to treatment regimens, which is critical for suppressing the virus and preventing transmission. The stability of this formulation allowed for global distribution of a reliable, once-daily therapy.

## Frequently asked questions

### What does How Gilead Stabilized the HIV Combination Pill Truvada cover?

A patent detailing a stable, fixed-dose combination of two HIV drugs, tenofovir disoproxil fumarate and emtricitabine, designed to prevent chemical breakdown in a single tablet.

### Who owns patent US 9744181?

Gilead Sciences Inc owns this patent, granted in 2017.

### When does this patent expire?

This patent is expected to expire on August 29, 2037, when the invention enters the public domain.

### What problem does this patent solve?

This technology is the backbone of Truvada, a landmark medication for both HIV treatment and pre-exposure prophylaxis (PrEP). By combining two drugs into one pill, it significantly improved patient adherence to treatment regimens, which is critical for suppressing the virus and preventing transmission. The stability of this formulation allowed for global distribution of a reliable, once-daily therapy.

### What does this patent NOT cover?

Does not cover the individual chemical compounds tenofovir disoproxil fumarate or emtricitabine themselves.

**Full plain-English explainer:** https://patentbrief.org/patent/us/9744181/harvoni-ledipasvir-sofosbuvir

**Original patent:** https://patents.google.com/patent/US9744181

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._